SPA14 liposomes combining saponin with fully synthetic TLR4 agonist provide adjuvanticity to hCMV vaccine candidate

MLA

Ernesto Luna, et al. “SPA14 Liposomes Combining Saponin with Fully Synthetic TLR4 Agonist Provide Adjuvanticity to HCMV Vaccine Candidate.” Npj Vaccines, vol. 9, no. 1, Dec. 2024, pp. 1–15. EBSCOhost, https://doi.org/10.1038/s41541-024-01046-0.

APA

Ernesto Luna, Sophie Ruiz, Marie Garinot, Cyril Chavagnac, Pankaj Agrawal, John Escobar, Laurent Revet, Marie-Jeanne Asensio, Fabienne Piras, Francis G. Fang, Donald R. Drake, Bachra Rokbi, Daniel Larocque, & Jean Haensler. (2024). SPA14 liposomes combining saponin with fully synthetic TLR4 agonist provide adjuvanticity to hCMV vaccine candidate. Npj Vaccines, 9(1), 1–15. https://doi.org/10.1038/s41541-024-01046-0

Chicago

Ernesto Luna, Sophie Ruiz, Marie Garinot, Cyril Chavagnac, Pankaj Agrawal, John Escobar, Laurent Revet, et al. 2024. “SPA14 Liposomes Combining Saponin with Fully Synthetic TLR4 Agonist Provide Adjuvanticity to HCMV Vaccine Candidate.” Npj Vaccines 9 (1): 1–15. doi:10.1038/s41541-024-01046-0.